Breaking News

Q BioMed, Mannin Research Accelerate COVID-19 Response Initiatives

Leveraging Mannin’s Tie2 based small molecule platform to address vascular leakage, a life-threatening COVID-19 complication

By: Contract Pharma

Contract Pharma Staff

Q BioMed Inc., and its technology partner, Mannin Research, are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. The drug program is being evaluated by government programs for funding and accelerated development under various COVID-19 response initiatives. The companies hope to have at least one treatment in human trials this year. The accelerated development is the result of joint venture (JV...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters